Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma

Anat Galor; Sandra J. Ference; Arun D. Singh; Michael S. Lee; Glen H.J. Stevens; Victor L. Perez; David M. Peereboom

doi:10.1016/j.ajo.2007.03.057

Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma

Anat Galor
, Sandra J. Ference
, Arun D. Singh
, Michael S. Lee
, Glen H.J. Stevens
, Victor L. Perez
, David M. Peereboom

Ophthalmology & Visual Neurosciences

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.

Original language	English (US)
Pages (from-to)	45-49.e2
Journal	American journal of ophthalmology
Volume	144
Issue number	1
DOIs	https://doi.org/10.1016/j.ajo.2007.03.057
State	Published - Jul 2007

Bibliographical note

Funding Information:
This study was supported by an unrestricted grant from Research to Prevent Blindness, New York, New York (Dr Lee), Research Support Schering Plough, Kenilworth, New Jersey (Dr Peereboom), Research Support Genetech, San Francisco, California (Dr Peereboom), and UCB Pharma, Smyrna, Georgia grant support (Dr Stevens). Financial conflict of interest is the same as support. Involved in design and conduct of the study (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); collection (A.G., S.J.F.); management (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); analysis (A.G., A.D.S., S.J.F.); interpretation of the data (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); preparation (A.G., A.D.S., S.J.F.); and review and approval of the manuscript (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1016/j.ajo.2007.03.057

Find It

Find It at U of M Libraries

Cite this

@article{f6fcc9a5341d46088e1ed933013155a5,

title = "Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma",

abstract = "Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54\%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.",

author = "Anat Galor and Ference, \{Sandra J.\} and Singh, \{Arun D.\} and Lee, \{Michael S.\} and Stevens, \{Glen H.J.\} and Perez, \{Victor L.\} and Peereboom, \{David M.\}",

note = "Funding Information: This study was supported by an unrestricted grant from Research to Prevent Blindness, New York, New York (Dr Lee), Research Support Schering Plough, Kenilworth, New Jersey (Dr Peereboom), Research Support Genetech, San Francisco, California (Dr Peereboom), and UCB Pharma, Smyrna, Georgia grant support (Dr Stevens). Financial conflict of interest is the same as support. Involved in design and conduct of the study (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); collection (A.G., S.J.F.); management (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); analysis (A.G., A.D.S., S.J.F.); interpretation of the data (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); preparation (A.G., A.D.S., S.J.F.); and review and approval of the manuscript (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.). ",

year = "2007",

month = jul,

doi = "10.1016/j.ajo.2007.03.057",

language = "English (US)",

volume = "144",

pages = "45--49.e2",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma

AU - Galor, Anat

AU - Ference, Sandra J.

AU - Singh, Arun D.

AU - Lee, Michael S.

AU - Stevens, Glen H.J.

AU - Perez, Victor L.

AU - Peereboom, David M.

N1 - Funding Information: This study was supported by an unrestricted grant from Research to Prevent Blindness, New York, New York (Dr Lee), Research Support Schering Plough, Kenilworth, New Jersey (Dr Peereboom), Research Support Genetech, San Francisco, California (Dr Peereboom), and UCB Pharma, Smyrna, Georgia grant support (Dr Stevens). Financial conflict of interest is the same as support. Involved in design and conduct of the study (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); collection (A.G., S.J.F.); management (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); analysis (A.G., A.D.S., S.J.F.); interpretation of the data (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.); preparation (A.G., A.D.S., S.J.F.); and review and approval of the manuscript (A.G., S.J.F., A.D.S., M.S.L., G.H.J.S., V.L.P., D.M.P.).

PY - 2007/7

Y1 - 2007/7

N2 - Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.

AB - Purpose: To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design: Retrospective case series. Methods: Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results: Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions: Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.

UR - https://www.scopus.com/pages/publications/34250764922

UR - https://www.scopus.com/pages/publications/34250764922#tab=citedBy

U2 - 10.1016/j.ajo.2007.03.057

DO - 10.1016/j.ajo.2007.03.057

M3 - Article

C2 - 17601426

AN - SCOPUS:34250764922

SN - 0002-9394

VL - 144

SP - 45-49.e2

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 1

ER -

Maculopathy as a Complication of Blood-Brain Barrier Disruption in Patients with Central Nervous System Lymphoma

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this